Mozart Ther­a­peu­tics se­cures $25M ex­pan­sion to Se­ries A; Lian­Bio un­veils PhI­Ia da­ta for gas­tric can­cer treat­ment

Mozart Ther­a­peu­tics, a Seat­tle-based biotech cen­tered on de­vel­op­ing CD8 treg mod­u­la­tors to treat au­toim­mune and in­flam­ma­to­ry dis­eases, has raised $25 mil­lion from new in­vestors to ex­tend its Se­ries A. Mozart’s ex­ist­ing in­vestors in­clude Sofinno­va Part­ners, Eli Lil­ly & Com­pa­ny, ARCH Ven­ture Part­ners, Mer­ck’s MRL Ven­tures Fund, Leaps by Bay­er, Al­ti­tude Life Sci­ence Ven­tures and Alexan­dria Ven­ture In­vest­ments.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER